OBJECTIVES: To assess the safety, acceptability, and preliminary efficacy of a culturally-adapted disclosure intervention for perinatally HIV-infected combined antiretroviral therapy patients in Haiti and the Dominican Republic. DESIGN: A quasi-experimental trial was conducted comparing caregiver-youth pairs who completed the intervention [adapted Blasini disclosure model (aBDM)] to pairs who discontinued aBDM participation before disclosure. aBDM consists of five components: structured healthcare worker training; one-on one pre-disclosure intervention/education sessions for youth (describing pediatric chronic diseases including cancer, diabetes and HIV) and for caregivers (strengthening capacity for disclosure); a scheduled supportive disclosure session; and one-on-one postdisclosure support for caregivers and youth. METHODS: Caregivers of nondisclosed combined antiretroviral therapy patients aged 10.0-17.8 years were invited to participate. Data were collected by separate one-on-one face-to-face interviews of caregivers and youth by study staff and medical record review by pediatricians at enrollment and 3 months after disclosure or after intervention discontinuation. RESULTS: To date, 65 Dominican Republic and 27 Haiti caregiver-youth pairs have enrolled. At enrollment, only 46.4% of youth had viral suppression and 43.4% of caregivers had clinically significant depressive symptomatology. To date, two serious study-related adverse events have occurred. Seven of the 92 (7.6%, 6 in the Dominican Republic) enrolled pairs discontinued participation before disclosure and 39 had completed postdisclosure participation. Median plasma HIV-RNA concentration was lower in youth who completed aBDM than in youth who discontinued participation before aBDM disclosure (<40 versus 8673 copies/ml; P = 0.027). Completers expressed considerable satisfaction with aBDM. CONCLUSION: Preliminary results suggest safety, acceptability, and possible effectiveness of the aBDM.
OBJECTIVES: To assess the safety, acceptability, and preliminary efficacy of a culturally-adapted disclosure intervention for perinatally HIV-infected combined antiretroviral therapy patients in Haiti and the Dominican Republic. DESIGN: A quasi-experimental trial was conducted comparing caregiver-youth pairs who completed the intervention [adapted Blasini disclosure model (aBDM)] to pairs who discontinued aBDM participation before disclosure. aBDM consists of five components: structured healthcare worker training; one-on one pre-disclosure intervention/education sessions for youth (describing pediatric chronic diseases including cancer, diabetes and HIV) and for caregivers (strengthening capacity for disclosure); a scheduled supportive disclosure session; and one-on-one postdisclosure support for caregivers and youth. METHODS: Caregivers of nondisclosed combined antiretroviral therapy patients aged 10.0-17.8 years were invited to participate. Data were collected by separate one-on-one face-to-face interviews of caregivers and youth by study staff and medical record review by pediatricians at enrollment and 3 months after disclosure or after intervention discontinuation. RESULTS: To date, 65 Dominican Republic and 27 Haiti caregiver-youth pairs have enrolled. At enrollment, only 46.4% of youth had viral suppression and 43.4% of caregivers had clinically significant depressive symptomatology. To date, two serious study-related adverse events have occurred. Seven of the 92 (7.6%, 6 in the Dominican Republic) enrolled pairs discontinued participation before disclosure and 39 had completed postdisclosure participation. Median plasma HIV-RNA concentration was lower in youth who completed aBDM than in youth who discontinued participation before aBDM disclosure (<40 versus 8673 copies/ml; P = 0.027). Completers expressed considerable satisfaction with aBDM. CONCLUSION: Preliminary results suggest safety, acceptability, and possible effectiveness of the aBDM.
Authors: Julian Harris; Mara Pillinger; Deborah Fromstein; Bayardo Gomez; Ivelisse Garris; Peter A Kanetsky; Pablo Tebas; Robert Gross Journal: AIDS Behav Date: 2011-10
Authors: Consuelo M Beck-Sagué; Jessy G Dévieux; María Claudia Pinzón-Iregui; Rosa Abreu-Pérez; Leonel Lerebours-Nadal; Stephanie Gaston; Andrew G Dean; Mina Halpern; Vanessa Rouzier; Rachel Bertrand; Rhonda Rosenberg; Jean William Pape; Stephen W Nicholas; Ileana Blasini Journal: J Trop Pediatr Date: 2014-11-10 Impact factor: 1.165
Authors: Robert Malow; Jessy G Dévieux; Judith A Stein; Rhonda Rosenberg; Michele Jean-Gilles; Jennifer Attonito; Serena P Koenig; Giuseppe Raviola; Patrice Sévère; Jean W Pape Journal: AIDS Behav Date: 2013-05
Authors: Jerilynn Radcliffe; Courtney Landau Fleisher; Linda A Hawkins; Mary Tanney; Nancy Kassam-Adams; Christine Ambrose; Bret J Rudy Journal: AIDS Patient Care STDS Date: 2007-07 Impact factor: 5.078
Authors: Anjuli D Wagner; Gabrielle OʼMalley; Olivia Firdawsi; Cyrus Mugo; Irene N Njuguna; Elizabeth Maleche-Obimbo; Irene W Inwani; Dalton C Wamalwa; Grace C John-Stewart; Jennifer A Slyker Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Lindsey K Reif; Rachel Bertrand; Charles Benedict; Matthew R Lamb; Vanessa Rouzier; Rose Verdier; Warren D Johnson; Jean W Pape; Daniel W Fitzgerald; Louise Kuhn; Margaret L McNairy Journal: J Int AIDS Soc Date: 2016-07-04 Impact factor: 5.396